Get the Stockscreener App
9.00
5.76%
0.49
Dbv Technologies Adr stock is traded at $9.00, with a volume of 24,525.
It is up +5.76% in the last 24 hours and down -14.20% over the past month.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
See More
Previous Close:
$8.51
Open:
$9.26
24h Volume:
24,525
Relative Volume:
0.47
Market Cap:
$246.51M
Revenue:
-
Net Income/Loss:
$-102.09M
P/E Ratio:
-8.5714
EPS:
-1.05
Net Cash Flow:
$-108.72M
1W Performance:
-4.81%
1M Performance:
-14.20%
6M Performance:
+113.02%
1Y Performance:
+89.47%
1-Day Range:
$8.8008
$9.54
1-Week Range:
$8.51
$10.93
52-Week Range:
$2.2045
$12.78
Dbv Technologies Adr Stock (DBVT) Company Profile
Name
Dbv Technologies Adr
Sector
Industry
Phone
33(0)155427878
Address
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Compare DBVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
9.00 | 232.73M | 0 | -102.09M | -108.72M | -1.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-29-25 | Resumed | Goldman | Sell |
| Jan-04-23 | Upgrade | Societe Generale | Hold → Buy |
| Dec-16-22 | Downgrade | Goldman | Neutral → Sell |
| May-10-22 | Downgrade | Goldman | Buy → Neutral |
| Sep-14-21 | Upgrade | Societe Generale | Hold → Buy |
| Jan-22-21 | Downgrade | Societe Generale | Hold → Sell |
| Nov-02-20 | Upgrade | Societe Generale | Sell → Hold |
| Aug-06-20 | Downgrade | Societe Generale | Buy → Sell |
| Aug-05-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-17-20 | Downgrade | Stifel | Buy → Hold |
| Jan-09-20 | Upgrade | Stifel | Hold → Buy |
| Dec-16-19 | Initiated | Citigroup | Buy |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Jun-17-19 | Initiated | Goldman | Buy |
| Dec-20-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-20-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-20-18 | Downgrade | Jefferies | Buy → Hold |
| Dec-20-18 | Downgrade | Stifel | Buy → Hold |
| Oct-31-17 | Upgrade | Societe Generale | Sell → Hold |
| Oct-24-17 | Downgrade | Societe Generale | Buy → Sell |
| Oct-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-23-17 | Initiated | Deutsche Bank | Buy |
| Mar-16-17 | Upgrade | Societe Generale | Hold → Buy |
| Sep-26-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-03-15 | Initiated | Barclays | Overweight |
| Oct-23-15 | Initiated | BofA/Merrill | Buy |
View All
Dbv Technologies Adr Stock (DBVT) Latest News
HC Wainwright Lowers Earnings Estimates for DBV Technologies - Defense World
DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report - GlobeNewswire
DBV Technologies S.A. - Via Ritzau
DBV Technologies Releases Latest Financial Report: Food Allergy Treatment Progress Updates Inside - Stock Titan
DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results - GlobeNewswire
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - GlobeNewswire
DBV Technologies Liquidity Contract Update: Over €3M in Trading Volume Reveals Market Activity - Stock Titan
DBV Technologies (DBVT) Projected to Post Quarterly Earnings on Tuesday - Defense World
DBV Technologies S.A. (NASDAQ:DBVT) Receives $14.75 Average PT from Analysts - Defense World
European ADRs Inch Higher As Drugmakers Shine - Finimize
DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer - GlobeNewswire
DBV Technologies Taps Healthcare Veteran as CHRO to Drive Commercial Evolution - Stock Titan
What analysts say about DBV Technologies S.A. Depositary Receipt stockHigh-impact stock picks - Autocar Professional
European Stocks In The US Finish With A Modest Rebound - Finimize
European ADRs Climb As Verona Pharma Leads Gains - Finimize
European ADRs Climb As Sequans Leads The Charge - Finimize
DBV Technologies’ SWOT analysis: peanut allergy patch stock poised for growth - Investing.com India
DBV Technologies (NASDAQ:DBVT) Upgraded to Hold at Wall Street Zen - Defense World
European Stocks Climb As ADRs Post Gains - Finimize
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
European ADRs: Navigating Sectoral Divergence in a Volatile Market - AInvest
Lifesci Capital Upgrades DBV Technologies (NASDAQ:DBVT) to Strong-Buy - Defense World
European Biopharma Leads Gains In ADR Market Surge - Finimize
European Biotech ADRs Lead the Charge: A Sector on the Verge of Breakthrough Growth - AInvest
European ADRs Dip As Biotech Stocks Show Mixed Results - Finimize
DBV Technologies stock holds steady as JMP reiterates $21 price target - Investing.com
Breakthrough Peanut Allergy Treatment Enters Critical Phase 3 Trial for Toddlers as Young as 12 Months - Stock Titan
European ADRs Dip As Evaxion And Grifols Climb - Finimize
European ADRs Dip While Biotech And Energy See Gains - Finimize
European Stocks Shine As ADRs Climb Higher - Finimize
DBV Technologies (NASDAQ:DBVT) Stock Price Crosses Above 50 Day Moving Average – Here’s Why - Defense World
DBV Technologies to Participate in Upcoming EAACI Congress 2025 - The Manila Times
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting - GlobeNewswire
DBV Technologies Secures Full Shareholder Support at Annual Meeting: Key Governance Updates - Stock Titan
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document - GlobeNewswire
DBV Technologies Reveals Special CEO Pay Package Ahead of Critical Shareholder Vote - Stock Titan
European ADRs Climb With Biotech Stocks Leading The Charge - Finimize
European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize
DBV Technologies (NASDAQ:DBVT) Raised to Sell at The Goldman Sachs Group - Defense World
Goldman Sachs cuts DBV Technologies stock to Sell, target EUR1.30 By Investing.com - Investing.com South Africa
Goldman Sachs cuts DBV Technologies stock to Sell, target EUR1.30 - Investing.com India
Goldman Sachs reinstates DBV Technologies with sell rating, $7.25 target By Investing.com - Investing.com India
Goldman Sachs reinstates DBV Technologies with sell rating, $7.25 target - Investing.com
Dbv Technologies Adr Stock (DBVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dbv Technologies Adr Stock (DBVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mohideen Pharis | Chief Medical Officer |
May 22 '25 |
Sale |
1.84 |
397 |
730 |
110,113 |
| Mohideen Pharis | Chief Medical Officer |
Jan 30 '25 |
Sale |
0.85 |
600 |
510 |
110,510 |
| Mohideen Pharis | Chief Medical Officer |
Nov 25 '24 |
Sale |
0.57 |
565 |
322 |
111,110 |
| Mohideen Pharis | Chief Medical Officer |
Nov 22 '24 |
Sale |
0.53 |
342 |
181 |
111,675 |
| Mohideen Pharis | Chief Medical Officer |
Nov 21 '24 |
Sale |
0.54 |
2,350 |
1,269 |
112,017 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):